Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Am J Clin Pathol ; 150(5): 393-405, 2018 Oct 01.
Article in English | MEDLINE | ID: mdl-30052721

ABSTRACT

OBJECTIVES: To assess bone marrow (BM) sampling in academic medical centers. METHODS: Data from 6,374 BM samples obtained in 32 centers in 2001 and 2011, including core length (CL), were analyzed. RESULTS: BM included a biopsy (BMB; 93%) specimen, aspirate (BMA; 92%) specimen, or both (83%). The median (SD) CL was 12 (8.5) mm, and evaluable marrow was 9 (7.6) mm. Tissue contraction due to processing was 15%. BMB specimens were longer in adults younger than 60 years, men, and bilateral, staging, and baseline samples. Only 4% of BMB and 2% of BMB/BMA samples were deemed inadequate for diagnosis. BM for plasma cell dyscrasias, nonphysician operators, and ancillary studies usage increased, while bilateral sampling decreased over the decade. BM-related quality assurance programs are infrequent. CONCLUSIONS: CL is shorter than recommended and varies with patient age and sex, clinical circumstances, and center experience. While pathologists render diagnoses on most cases irrespective of CL, BMB yield improvement is desirable.


Subject(s)
Bone Marrow Diseases/pathology , Bone Marrow/pathology , Adolescent , Adult , Aged , Aged, 80 and over , Biopsy, Large-Core Needle , Bone Marrow Diseases/diagnosis , Bone Marrow Examination/standards , Canada , Child , Child, Preschool , Cross-Sectional Studies , Female , Humans , Infant , Male , Middle Aged , Retrospective Studies , United States , Young Adult
3.
Nature ; 553(7688): 281, 2018 Jan.
Article in English | MEDLINE | ID: mdl-32094634
4.
Nature ; 548(7666): 158, 2017 08 09.
Article in English | MEDLINE | ID: mdl-28796209
5.
Nature ; 544(7649): 161, 2017 04 12.
Article in English | MEDLINE | ID: mdl-28406195
6.
Cancer Genet ; 207(3): 98-102, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24704113

ABSTRACT

Single nucleotide polymorphism (SNP)-based chromosome microarray analysis was used to uncover copy neutral loss of heterozygosity (LOH) in the long arm of chromosome 20 in blood or bone marrow specimens from three patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). All three patients presented with lymph node enlargement. Whereas one of the patients has had a complicated clinical course, the other two have a more indolent disease. Sequence analysis of the tumor suppressor gene ASXL1, which is located in 20q and is commonly mutated in malignant myeloid diseases and occasionally in CLL/SLL specimens, revealed no mutations in our three patients with copy neutral LOH in 20q. The possible contribution of other imprinted microRNAs and antisense genes residing in 20q to the pathogenesis of a subset of CLL/SLL patients is discussed. These findings illustrate the value of SNP arrays for the detection of novel recurrent genomic alterations that may contribute to CLL/SLL onset or progression.


Subject(s)
Chromosomes, Human, Pair 20 , Heterozygote , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Humans , Polymorphism, Single Nucleotide
9.
Leuk Lymphoma ; 51(1): 89-94, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19863176

ABSTRACT

Pediatric nodal marginal zone lymphoma (NMZL) is described as a separate variant of NMZL in the most recent WHO classification of tumors of hematologic and lymphoid tissues. It has distinctive morphology and clinical presentation and stands out as an indolent disease with remarkably better overall prognosis compared to classic NMZL. Here we report two adult patients with NMZL with clinical and morphologic features consistent with pediatric NMZL (pNMZL) and review available literature describing the clinical and histologic presentation of pNMZL. Two men, ages 44 and 18 years, each presented with localized cervical lymphadenopathy, both demonstrated florid proliferation of the marginal zone and disruption of reactive germinal centers, progressive transformation of germinal centers-like morphologic features typical for pNMZL and clonal disease with immunophenotype consistent with NMZL. This is the first report of pNMZL in a middle-aged person. Distinct histologic features and characteristic benign clinical course will help to distinguish this rare variant from other NMZL in the adults. Clinically, recognition is important to understand the true incidence of this rare form in the adult population and to avoid unnecessary overtreatment of this indolent form.


Subject(s)
Lymphoma, B-Cell, Marginal Zone/diagnosis , Medical Oncology/methods , Adolescent , Adult , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Murine-Derived , Antineoplastic Agents/therapeutic use , Flow Cytometry/methods , Humans , Immunophenotyping , Immunotherapy/methods , Lymphatic Diseases/diagnosis , Lymphatic Diseases/pathology , Lymphoma, B-Cell, Marginal Zone/immunology , Lymphoma, B-Cell, Marginal Zone/surgery , Lymphoma, B-Cell, Marginal Zone/therapy , Male , Prognosis , Remission Induction , Rituximab , Treatment Outcome
11.
Clin Lung Cancer ; 10(6): 438-40, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19900863

ABSTRACT

Cisplatin-based chemotherapy has become an accepted standard in the adjuvant treatment of non-small-cell lung cancer (NSCLC). We present a case of acute myelogenous leukemia with an 11q23/MLL rearrangement diagnosed 1 year after the completion of 4 cycles of cisplatin and vinorelbine for resected NSCLC. To our knowledge, this is the first case of therapy-related acute myelogenous leukemia (t-AML) associated with this chemotherapy combination. The literature on t-AML with the 11q23/MLL rearrangement is reviewed.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Leukemia, Myeloid, Acute/chemically induced , Translocation, Genetic/drug effects , Aged , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Chromosomes, Human, Pair 11 , Cisplatin/administration & dosage , Follow-Up Studies , Histone-Lysine N-Methyltransferase , Humans , Leukemia, Myeloid, Acute/genetics , Lung Neoplasms/drug therapy , Male , Myeloid-Lymphoid Leukemia Protein/genetics , Vinblastine/administration & dosage , Vinblastine/analogs & derivatives , Vinorelbine
12.
Am J Clin Pathol ; 130(4): 604-12, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18794054

ABSTRACT

The effect of rituximab on malignant B cells and normal circulating B cells has been previously studied. In contrast, data on the degree of depletion of nonneoplastic B cells induced by rituximab in lymph nodes and spleen is limited. For this purpose, clinical charts, autopsy records, lymph node and spleen sections, and immunoperoxidase stains were reviewed from 10 patients who had received 1 to 40 doses of rituximab before death. The percentage of nonneoplastic B cells was lower in the lymph node and spleen in rituximab-treated patients when compared with cyclophosphamide, doxorubicin, vincristine, and prednisone-treated patients and patients without lymphoma. The effect of rituximab on nonneoplastic B cells was observed as soon as 1 month after administration and with as few as 3 doses. Reappearance of normal numbers of B cells was not observed 1 to 12 months after the last dose of rituximab was administered. We conclude that rituximab induces prompt, consistent, profound, and prolonged depletion of B lymphocyte populations in human lymphoid tissue.


Subject(s)
Antibodies, Monoclonal/pharmacology , Antineoplastic Agents/pharmacology , B-Lymphocytes/drug effects , Lymph Nodes/drug effects , Spleen/drug effects , Adolescent , Adult , Antibodies, Monoclonal, Murine-Derived , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Autopsy , Child , Cyclophosphamide/therapeutic use , Doxorubicin/therapeutic use , Female , Humans , Immunohistochemistry , Lymphoma, B-Cell/drug therapy , Male , Middle Aged , Prednisone/therapeutic use , Rituximab , Vincristine/therapeutic use
13.
J Med Libr Assoc ; 94(2): 198-205, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16636713

ABSTRACT

OBJECTIVES: The paper (1) introduces health sciences librarians to the main concepts and principles of the Semantic Web (SW) and (2) briefly reviews a number of projects on the handling of biomedical information that uses SW technology. METHODOLOGY: The paper is structured into two main parts. "Semantic Web Technology" provides a high-level description, with examples, of the main standards and concepts: extensible markup language (XML), Resource Description Framework (RDF), RDF Schema (RDFS), ontologies, and their utility in information retrieval, concluding with mention of more advanced SW languages and their characteristics. "Semantic Web Applications and Research Projects in the Biomedical Field" is a brief review of the Unified Medical Language System (UMLS), Generalised Architecture for Languages, Encyclopedias and Nomenclatures in Medicine (GALEN), HealthCyberMap, LinkBase, and the thesaurus of the National Cancer Institute (NCI). The paper also mentions other benefits and by-products of the SW, citing projects related to them. DISCUSSION AND CONCLUSIONS: Some of the problems facing the SW vision are presented, especially the ways in which the librarians' expertise in organizing knowledge and in structuring information may contribute to SW projects.


Subject(s)
Internet , Libraries, Medical , Online Systems/instrumentation , Semantics , Humans , Information Storage and Retrieval/methods , Vocabulary, Controlled
14.
J Biol Chem ; 278(48): 48154-61, 2003 Nov 28.
Article in English | MEDLINE | ID: mdl-12972433

ABSTRACT

Endothelin-1 (ET-1) is an autocrine factor in the mammalian heart important in enhancing cardiac performance, protecting against myocardial ischemia, and initiating the development of cardiac hypertrophy. The ETA receptor is a seven-transmembrane G-protein-coupled receptor whose precise subcellular localization in cardiac muscle is unknown. Here we used fluorescein ET-1 and 125I-ET-1 to provide evidence for ET-1 receptors in cardiac transverse tubules (T-tubules). Moreover, the ETA receptor and downstream effector phospholipase C-beta 1 were co-localized within T-tubules using standard immunofluorescence techniques, and protein kinase C (PKC)-epsilon-enhanced green fluorescent protein bound reversibly to T-tubules upon activation. Localized photorelease of diacylglycerol further suggested compartmentation of PKC signaling, with release at the myocyte "surface" mimicking the negative inotropic effects of bath-applied PKC activators and "deep" release mimicking the positive inotropic effect of ET-1. The functional significance of T-tubular ET-1 receptors was further tested by rendering the T-tubule lumen inaccessible to bath-applied ET-1. Such "detubulated" cardiac myocytes showed no positive inotropic response to 20 nM ET-1, despite retaining both a nearly normal twitch response to field stimulation and a robust positive inotropic response to 20 nm isoproterenol. We propose that ET-1 enhances myocyte contractility by activating ETA receptor-phospholipase C-beta 1-PKC-epsilon signaling complexes preferentially localized in cardiac T-tubules. Compartmentation of ET-1 signaling complexes may explain the discordant effects of ET-1 versus bath applied PKC activators and may contribute to both the specificity and diversity of the cardiac actions of ET-1.


Subject(s)
Myocardium/metabolism , Myocytes, Cardiac/physiology , Receptors, Endothelin/metabolism , Animals , Blotting, Western , Dogs , Dose-Response Relationship, Drug , Endothelin-1/metabolism , Fluorescein/pharmacology , Green Fluorescent Proteins , Heart Ventricles/metabolism , Isoenzymes/metabolism , Isoproterenol/pharmacology , Kinetics , Luminescent Proteins/metabolism , Male , Microscopy, Fluorescence , Models, Biological , Models, Chemical , Myocardium/cytology , Myocytes, Cardiac/metabolism , Phospholipase C beta , Photons , Protein Binding , Protein Kinase C/metabolism , Protein Kinase C-epsilon , Rats , Rats, Sprague-Dawley , Signal Transduction , Type C Phospholipases/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...